NEW YORK (360Dx) – Hepatitis C virus RNA testing at the point of care could provide an advantage over antibody testing by enabling diagnosis of active infection in a single visit, according to a recent study conducted by researchers in Australia.

These point-of-care tests can play a vital role to ensure that people receive proper treatment, said Jason Grebely, an associate professor at the Kirby Institute, University of New South Wales in Sydney, Australia, who conducts point-of-care HCV testing for substance users.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.